stockrowTG Therapeutics, Inc.
TGTX Healthcare Biotechnology
TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.
- Revenue
- +70.3%
- EPS
- −73.7%
- Free cash flow
- +427.1%
- Total debt
- +204.2%
Quarter to June 2026, against a year earlier
Follow TGTX
Alert me
TG Therapeutics, Inc. (TGTX) Shares outstanding
TG Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $161.4M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $157.3M. Over the past ten years it has ranged from $45.6M (fiscal 2015) to $161.4M (fiscal 2025) — the current reading is the highest in ten years. TG Therapeutics, Inc. ranks 71st of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $161.4M | 0.67% |
| FY2024 | $160.3M | 7.96% |
| FY2023 | $148.5M | 9.67% |
| FY2022 | $135.4M | 2.41% |
| FY2021 | $132.2M | 14.64% |
| FY2020 | $115.3M | 30.51% |
| FY2019 | $88.4M | 17.10% |
| FY2018 | $75.5M | 21.58% |
| FY2017 | $62.1M | 26.57% |
| FY2016 | $49.0M | 7.44% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $157.3M | (1.74%) |
| Mar 2026 | $160.1M | (0.84%) |
| Dec 2025 | $161.4M | 0.26% |
| Sep 2025 | $161.0M | (0.96%) |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IBRX ImmunityBio, Inc. compare | $1.1B |
| CAI Caris Life Sciences,�Inc. compare | $295.1M |
| TGTX TG Therapeutics, Inc. | $157.3M |
| CYTK Cytokinetics, Incorporated compare | $132.1M |
| SYRE Spyre Therapeutics, Inc. compare | $88.4M |
| PTGX Protagonist Therapeutics, Inc. compare | $71.0M |
| TWST Twist Bioscience Corporation compare | $62.4M |
| KRYS Krystal Biotech, Inc. compare | $30.8M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $30.3M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on TGTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement